Dendreon Corp fka DNDNQ

[iwfal]

I respectfully disagree.

Program-survival bias — as opposed to the various other biases in phase-2 trials — would pertain even if phase-3 studies were exact clones of the phase-2 studies in trial design and size.

It is amusing to me how often these discussions come down to semantics. What is the precise definition of PSB? Of "power analysis"? (pertinent to a different conversation I had with Toos on the IV board), ...